194608-84-9

Upstream product

• 79558-49-9 2,4-dihydroxy-3-propylphenyl ethyl ketone 
• 194792-52-4 methyl 3-chloro-4-(3-bromopropylthio)-phenylacetate 
• 57017-95-5 methyl 3-chloro-4-hydroxyphenylacetate 
• 91361-78-3 3-chloro-4-dimethylcarbamoylthio-phenylacetic acid methyl ester 
• 91373-91-0 (3-chloro-4-dimethylthiocarbamoyloxyphenyl)acetic acid methyl ester 
• 74815-88-6 2,4-dihydroxy-3-allylpropiophenone 
• 5792-36-9 2',4'-dihydroxypropiophenone 

Downstream Products

• 194608-87-2 {3-chloro-4-[3-(3-ethyl-7-propyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 194608-85-0 {3-Chloro-4-[3-(3-hydroxy-4-{1-[(E)-hydroxyimino]-propyl}-2-propyl-phenoxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 

Relevant academic research and scientific papers

Phenylacetic acid derivatives as hPPAR agonists

Beginning with the weakly active lead structure 1, a new series of hPPAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. F

Benzisoxazole-derived antidiabetic compounds

The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.